

CME

The SA Journal of CPD
Officially Accredited
for CPD Points

JUNE 2009



Parasitic diseases

- The returning traveller
- Parasites and the skin
- Parasitic infections in HIV
- Schistosomiasis
- *Taenia* and *Echinococcus* infections in humans
- Nematodes
- Amoebiasis

Forthcoming Titles

July: Vascular surgery

- Carotid disease
- Aneurysmal disease
- Claudication of the lower limb
- Venous thrombosis
- HIV-associated vasculopathy
- Varicose veins
- The diabetic foot

August: ENT


- Parotid tumours
- Rhinosinusitis
- Dysphagia
- Chronic otitis media
- Allergic rhinitis
- Infant hearing loss
- The dizzy patient
- Blocked ears

CME

MAINTAIN VASCULAR
FLOW WITHOUT
OBSTRUCTING CASH FLOW!



you're the expert in your field,
we're the expert in ours!



but we're more than just a claims switch...

we help you to better track claim responses, reconcile remittance advices,
collect from your patients and manage your practice performance.

isn't it time you spoke to the experts?



healthbridge is trusted by more than 6000 medical practitioners, all major hospital,
optometry, pathology and radiology groups and accesses all medical aids.

web www.healthbridge.co.za

client service centre 0860 200 222

a member of tradebridge

The Comfort Food for Flu



The Scientifically Proven Treatment for Flu

Strike fast
Tamiflu[®]
oseltamivir
Treat. Prevent. Protect.

- Symptom severity ↓ 38 %¹
- Duration of influenza ↓ 30 %¹
- Secondary lower respiratory tract complications ↓ 67 %²

References: 1. Treanor JJ, Hayden FG, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A Randomized Controlled Trial. JAMA 2000;283(8):1016-24.
2. Kaiser L, Wat C, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.

[S4] **TAMIFLU[®] 75 mg Capsules**: 40/20.2.8/0578 & **TAMIFLU[®] 12 mg/ml Powder for Oral Suspension**: 40/20.2.8/0579. Abbreviated product information. Please refer to the complete package insert for full information. **COMPOSITION**: Each capsule contains 75 mg oseltamivir. Each 1 g of powder for oral suspension contains 30 mg oseltamivir. Each 1 ml of the reconstituted suspension contains 12 mg oseltamivir. **INDICATIONS**: For treatment of influenza in adults and children ≥ 1 year of age. For prophylaxis of influenza in adults and adolescents ≥ 13 years of age. **DOSAGE**: Treatment should begin within the first or second day of onset of symptoms of influenza. **Adults and adolescents ≥ 13 years**: one 75 mg capsule twice daily, for 5 days. For prophylaxis: 75 mg once daily. **Children: > 40 kg or ≥ 8 years** who are able to swallow capsules, may also receive treatment with a 75 mg capsule twice daily as an alternative to **TAMIFLU 12 mg/ml Powder for Oral Suspension** (refer to the package insert for complete dosage schedule). **CONTRA-INDICATIONS**: Hypersensitivity to oseltamivir phosphate or to any component of the product. **TAMIFLU** should not be used during pregnancy and in mothers breastfeeding their infants. **WARNINGS AND PRECAUTIONS**: TAMIFLU is not a substitute for influenza vaccination. **SIDE-EFFECTS**: The most frequently reported adverse events are nausea and vomiting, abdominal pain, diarrhoea and headache. **PACK SIZES**: **TAMIFLU 75 mg Capsules**: blister packs containing 10 capsules. **TAMIFLU 12 mg/ml Powder for Oral Suspension**: 100 ml amber glass bottle with 30 g of powder for oral suspension. Full details are available from Roche Products (Pty) Ltd, PO Box 129, Isando, 1600. Tel: 011 928 8700 or Toll-free on REAL (Roche Ethical Assistance Line): 0800 21 21 25. 938 TAM

WITH NEW
CLOPIVAS
CLOPIDOGREL 75 MG

R195.00¹



• PROVEN BIOEQUIVALENCE²

• NO SIGNIFICANT DIFFERENCE VS THE INNOVATOR IN:
- MEAN % OF INHIBITION OF PLATELET AGGREGATION³
- BLEEDING TIME (SEC)³



REFERENCES:
1. SEP (excl. VAT) on 16/02/09
2. Data on file
3. Rao TRK, et al. "Bioequivalence and tolerability study of 2 brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures" Current Therapeutic Research, Nov/Dec 2003;64(9):685-696

Cipla Medpro (Pty) Ltd. Reg. No. 1995/004182/07. Rosen Heights, Pasita Street, Rosen Park, Bellville, 7530, Tel (021) 943 4200, Fax (021) 914 4699
Email: medpro@ciplamedpro.co.za, Website: www.cipla.co.za